Health Canada Approves Zepbound for OSA in Adults With Obesity
Tirzepatide injection becomes the first medication authorized in Canada for moderate to severe OSA, demonstrating significant reductions in breathing disruptions in clinical trials.
Category: Prescription Drugs
Prescription Drugs
Latest
Prescription Drugs
Latest
Steady-State Pharmacokinetics for Sublingual Tablet That Targets Nonrestorative Sleep Linked to Fibromyalgia
The peer-reviewed study highlights how the sublingual cyclobenzaprine formulation targets nonrestorative sleep and bypasses first-pass metabolism.
Prescription Drugs
Latest
FDA Approves First Non-Scheduled Drug for Cataplexy in Pediatric Narcolepsy Patients
The treatment was previously approved for excessive daytime sleepiness in pediatric patients 6 years of age and older with narcolepsy.
Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession
With the acquisition of Avadel Pharmaceuticals complete, Alkermes prepares to initiate phase 3 studies for its orexin agonist alixorexton while planning a leadership transition for mid-2026.
Read More
Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth
The low-sodium oxybate oral solution generated $1.7 billion in revenue, contributing to the company’s $3.1 billion neuroscience portfolio performance in 2025.
Read More
First Patient Dosed in Phase 3 Trial of Solriamfetol for Major Depressive Disorder with Excessive Daytime Sleepiness
The CLARITY trial utilizes a randomized withdrawal design to assess time to relapse of depressive symptoms in patients with major depressive disorder and excessive daytime sleepiness.
Read More
Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio
The acquisition accelerates Alkermes’ entry into the sleep medicine market and incorporates the FDA-approved extended-release sodium oxybate treatment for narcolepsy.
Read More
Amneal Receives FDA Approval for Sodium Oxybate Oral Solution
The approval allows Amneal to offer a generic alternative for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients, expanding access to this standard of care therapy.
Read More
Study: Specific Sleeping Pill Blocks Tau-Mediated Neurodegeneration in Mice
New research suggests the orexin receptor antagonist prevents harmful protein buildup in the brain.
Read More
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026
The company’s narcolepsy treatment shows strong growth, while its late-stage pipeline advances with five phase 3 trials and a novel orexin agonist.
Read More
Avadel Shareholders Approve Acquisition by Alkermes
The deal will bring the narcolepsy treatment LUMRYZ under the Alkermes portfolio.
Read More
Study Links Reduced Sleep Medication Use in Older Adults to Improved Health, Longevity
New modeling from the University of Southern California suggests avoiding prescription sleep drugs could lower fall risk and cognitive impairment while increasing life expectancy.
Read More
Daridorexant Improves Sleep, Daytime Function in Menopausal-Age Women With Insomnia
A new analysis of phase 3 trial data published in Maturitas supports the efficacy and safety of the dual orexin receptor antagonist for insomnia in this patient population.
Read More
Idorsia Insomnia Treatment Wins Prix Galien Bridges Award
The dual orexin receptor antagonist was honored as the ‘Best Biotechnology & Pharmaceutical Product’ in Europe-Middle East.
Read More
Alkermes Increases Offer to Acquire Avadel
The increased offer values Avadel at up to approximately $2.37 billion.
Read More
New Evidence Supports Xywav’s Benefits for Daytime, Nighttime Symptoms in Narcolepsy, IH
Phase 4 DUET trial and real-world data presented at World Sleep 2025 and Psych Congress 2025 highlight low-sodium Xywav’s impact on sleep continuity, alertness, and cardiometabolic risk profiles in adults with narcolepsy or idiopathic hypersomnia.
Read More
Sleep Apnea May Amplify GLP-1 Survival Benefits in Type 2 Diabetes
A study of nearly 1.8 million adults with diabetes suggests patients with obstructive sleep apnea derive a 20% greater mortality reduction from GLP-1 therapy than those without the sleep disorder.
Read More
Which Costs Less: GLP-1s or Bariatric Surgery?
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
Read More